SCHEMBL6434632

SCHEMBL6434632

CC(C)(C)OC(=O)c1ccccc1NS(=O)(=O)c1ccc2c(Cl)cnc(Cl)c2c1

nearest known ligand 0.55

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PLAU P00749 5/20 0.55
PLG P00747 3/20 0.55
LMNA P02545 5/20 0.52
MAPK1 P28482 1/20 0.52
KMT2A Q03164 3/20 0.46
MEN1 O00255 2/20 0.46
GAA P10253 2/20 0.44
SLC25A1 P53007 1/20 0.44
CCR2 P41597 3/20 0.43
CYP1A2 P05177 1/20 0.43
CYP3A4 P08684 1/20 0.43
CYP2D6 P10635 1/20 0.43
CYP2C9 P11712 1/20 0.43
CYP2C19 P33261 1/20 0.43
CCR4 P51679 1/20 0.43
CCR5 P51681 1/20 0.43
PLAT P00750 1/20 0.43
HTT P42858 2/20 0.42
KDM4E B2RXH2 1/20 0.42
NPC1 O15118 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6437969 0.86 PLAU (0.54) PLAUPLGLMNAMAPK1KMT2A
SCHEMBL6432817 0.84 PLG (0.74) PLAUPLGLMNAKMT2AMEN1
SCHEMBL6436568 0.82 PLG (0.56) PLAUPLGLMNAKMT2AMEN1
SCHEMBL6436403 0.76 PLAU (0.52) PLAUPLGGAAPLATHTT
SCHEMBL6434806 0.76 PLAU (0.54) PLAUPLGPLATKDM4EALDH1A1
SCHEMBL6436550 0.75 PLAU (0.58) PLAUPLGPLAT
SCHEMBL6433183 0.75 PLAU (0.53) PLAUPLGLMNAKMT2AMEN1
SCHEMBL6432675 0.74 PLAU (0.56) PLAUPLGGAAPLATKDM4E
SCHEMBL6437744 0.74 PLAU (0.56) PLAUPLGGAAPLATKDM4E
SCHEMBL6434690 0.74 PLAU (0.46) PLAUPLGKMT2AMEN1PLAT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20050026836-A1 Composition for the treatment of damaged tissue DACK KEVIN NEIL (GB) 2005-02-03 US disclosed
US-20030199440-A1 Composition for the treatment of damaged tissue PFIZER INC. 2003-10-23 US disclosed
EP-1077945-B1 ISOQUINOLINES AS UROKINASE INHIBITORS PFIZER (US) 2003-01-08 EP disclosed
EP-1242120-A2 COMBINATIONS OF GROWTH FACTORS AND I:UPA OR I:MMP FOR THE TREATMENT OF DAMAGED TISSUE Pfizer Limited (GB) 2002-09-25 EP disclosed
WO-2001049309-A2 COMBINATIONS OF GROWTH FACTORS AND I: UPA OR I: MMP FOR THE TREATMENT OF DAMAGED TISSUE PFIZER LIMITED (GB) 2001-07-12 WO disclosed
EP-1077945-A1 ISOQUINOLINES AS UROKINASE INHIBITORS PFIZER INC. (US) 2001-02-28 EP disclosed
US-6093731-A Isoquinolines PFIZER INC. 2000-07-25 US disclosed
WO-2000005214-A2 ISOQUINOLINES AS UROKINASE INHIBITORS PFIZER INC. (US) 2000-02-03 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030199440-A1 Composition for the treatment of damaged tissue MMP1, SERPINE1, COL14A1 PLAU 119/4885PLG 33/4885LMNA 1451/4885
US-20050026836-A1 Composition for the treatment of damaged tissue MMP1, SERPINE1, COL14A1 PLAU 119/4885PLG 33/4885LMNA 1451/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.